Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ASCO Annual Meeting Coverage

Set Alert for ASCO Coverage

Roche Stays Upbeat Amid Skepticism On Tiragolumab’s Chances

Analysts are keen to know more about the statistical weighting of Roche’s SKYSCRAPER 1 study of the TIGIT inhibitor, while Merck & Co can learn from their rival’s slip-up for their own trial design.

Cancer Companies

China At ASCO: Biotech Pharma, Akeso, Chongqing Precision Showcase Promising Data

EGFR-targeting antibody, anti-PD-1/CTLA4 bispecific antibody and CD19-targeting CAR-T therapy from emerging Chinese oncology companies shine at one of ASCO’s most-watched sessions.

China Clinical Trials

Stock Watch: Cancer Combination Therapies Face Rising Bar

Improving efficacy by combining drugs has been a mainstay of cancer therapy but adding new targeted drugs together based on very early-stage data is not working out, especially when one of the drugs is barely active on its own.

Stock Watch Companies

Amgen/Takeda ASCO Data Could Help Guide Vectibix Use In mCRC

The PARADIGM study took place in Japan, but it was described as the first to prospectively evaluate treatment of wild-type RAS mCRC and left-sided primary tumors.

ASCO Cancer

Gilead's Trodelvy Surpasses Investors' Low Bar At ASCO, But Faces A Commercial Climb

The Phase III TROPICS-02 study in HR-positive/HER2-negative breast cancer was successful, but data for rival drug Enhertu overshadowed the results.

Cancer ASCO

Mirati Seeks Differentiation, Amgen Invests In Combos To Dominate KRAS G12C Field

Amgen outlined the most frequent co-mutations in treatment-resistant lung and colorectal cancers at ASCO, while Mirati’s adagrasib showed efficacy in active CNS metastases in lung cancer patients. 

ASCO Clinical Trials

Neoantigen Cancer Vaccine Helps BioNTech Advance Oncology Ambitions

After many years of failures and setbacks, neoantigen-targeting immunotherapies are gaining momentum, with BioNTech and Roche among the frontrunners.

ASCO Cancer

ASCO: AstraZeneca's Enhertu Is Poised To Change The Breast Cancer Paradigm

The results of DESTINY-Breast04 could impact survival for approximately 50% of patients diagnosed with metastatic breast cancer today, principal investigator Modi said at the American Society of Clinical Oncology annual meeting.

ASCO Clinical Trials

Oncternal And SpringWorks Among Early ASCO Winners And Losers

While the big pharma names dominate the ASCO cancer congress, it is also a chance to shine for emerging small-to-medium biopharma companies.

Cancer Companies
See All